![Lawrence Kenyon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lawrence Kenyon
No open positions remaining
Net worth: 67 703 $ as of 2026-08-30
Profile
Lawrence A. Kenyon served as Chief Financial Officer, Secretary & EVP at NeoPharm, Inc. from 2000 to 2006.
Served as Director at Tamir Biotechnology, Inc. in 2009.
Served as Chief Financial Officer at Par Pharmaceutical, Inc. from 2009 to 2010.
Served as Chief Financial Officer & Executive Vice President at Endo Generics Holdings, Inc. from 2009 to 2010.
Served as President, CEO, CFO & Secretary at Tamir Biotechnology, Inc. in 2013.
Served as Chief Operating & Financial Officer at Arno Therapeutics, Inc. from 2014 to 2015.
Served as CEO, CFO, Secretary, Treasurer & Director at Outlook Therapeutics, Inc. from 2024 to 2025.
Attended the University of Wisconsin, completing undergraduate studies in 1987.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-08-13 | 106,956 ( 0.07% ) | 67 703 $ | 2026-08-30 |
Former positions of Lawrence Kenyon
| Companies | Position | End |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Chief Executive Officer | 2025-06-30 |
| ARNO THERAPEUTICS, INC. | Director of Finance/CFO | 2015-08-31 |
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Chief Executive Officer | 2013-03-30 |
Par Pharmaceutical, Inc.
 Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Director of Finance/CFO | 2010-06-30 |
| PAR PHARMACEUTICAL COMPANIES, INC. | Director of Finance/CFO | 2010-06-03 |
Training of Lawrence Kenyon
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
89
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Health Technology |
Endo Generics Holdings, Inc.
 Endo Generics Holdings, Inc. Pharmaceuticals: GenericHealth Technology Operates as a holding company with interests in developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States | Health Technology |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology Provides drug research, development and commercialization services | Health Technology |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Health Technology |
Arno Therapeutics, Inc.
 Arno Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs | Health Technology |
Outlook Therapeutics, Inc.
 Outlook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures bevacizumab therapeutic products | Health Technology |
- Stock Market
- Insiders
- Lawrence Kenyon
